Stocktoria
NovaBridge Biosciences NBP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-01-17
NovaBridge Biosciences statistics & valuation
Market cap$189.2M
P / B0.8×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | — | -11395.1% | 3422.2% | — |
| Net margin | — | — | -32868.5% | 23923.5% | -415.6% |
| FCF margin | — | — | -29107.9% | 10443.8% | -178.8% |
| Return on assets | -17.8% | -10.5% | -56.3% | -62.8% | -41.6% |
| Return on equity | -20.0% | -11.1% | -85.6% | -88.8% | -51.2% |
| Current ratio | 8.09 | 20.90 | 5.67 | 4.78 | 7.66 |
| Revenue growth | — | — | -140.7% | -101.8% | -94.3% |
Source: SEC EDGAR filings · CIK 0001778016 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.